CN113474339B - 作为malt1抑制剂的化合物的结晶形式 - Google Patents

作为malt1抑制剂的化合物的结晶形式 Download PDF

Info

Publication number
CN113474339B
CN113474339B CN202080015968.5A CN202080015968A CN113474339B CN 113474339 B CN113474339 B CN 113474339B CN 202080015968 A CN202080015968 A CN 202080015968A CN 113474339 B CN113474339 B CN 113474339B
Authority
CN
China
Prior art keywords
cancer
crystalline form
lymphoma
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080015968.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113474339A (zh
Inventor
C·雷斯
K·L·金佩
R·M·格尔特曼
魏昊娟
周鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN113474339A publication Critical patent/CN113474339A/zh
Application granted granted Critical
Publication of CN113474339B publication Critical patent/CN113474339B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080015968.5A 2019-02-22 2020-02-20 作为malt1抑制剂的化合物的结晶形式 Active CN113474339B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22
CNPCT/CN2019/075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (2)

Publication Number Publication Date
CN113474339A CN113474339A (zh) 2021-10-01
CN113474339B true CN113474339B (zh) 2025-02-25

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080015968.5A Active CN113474339B (zh) 2019-02-22 2020-02-20 作为malt1抑制剂的化合物的结晶形式

Country Status (21)

Country Link
US (1) US12269813B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927696B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523368A (cg-RX-API-DMAC7.html)
KR (1) KR20210131371A (cg-RX-API-DMAC7.html)
CN (1) CN113474339B (cg-RX-API-DMAC7.html)
AU (1) AU2020226723B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016400A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129623A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192320A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21067828A (cg-RX-API-DMAC7.html)
ES (1) ES2966132T3 (cg-RX-API-DMAC7.html)
IL (1) IL285675A (cg-RX-API-DMAC7.html)
JO (1) JOP20210227A1 (cg-RX-API-DMAC7.html)
MA (1) MA55019A (cg-RX-API-DMAC7.html)
MX (1) MX2021010133A (cg-RX-API-DMAC7.html)
PE (1) PE20212067A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552018A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108909SA (cg-RX-API-DMAC7.html)
TW (1) TW202045495A (cg-RX-API-DMAC7.html)
UY (1) UY38592A (cg-RX-API-DMAC7.html)
WO (1) WO2020169736A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
JP2023539729A (ja) 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤の非晶質形態及びその製剤
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
KR20230154227A (ko) 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
WO2023016995A1 (en) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
AU2024357109A1 (en) 2023-10-06 2026-03-12 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119036A1 (en) * 2016-12-21 2018-06-28 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622571A4 (en) 2003-04-30 2012-05-02 Agensys Inc NUCLEIC ACIDS AND CORRESPONDING PROTEINS NAMED 109P1D4 FOR THE TREATMENT AND DETECTION OF CANCER
KR20090007347A (ko) * 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 c-MET 단백질 키나제 억제제
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
WO2011161612A1 (en) 2010-06-22 2011-12-29 Basf Se Process for preparing 4-hydroxypyridines
JP6231085B2 (ja) * 2012-05-31 2017-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アミノキナゾリン誘導体及びピリドピリミジン誘導体
JP6545197B2 (ja) 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
MX2017001656A (es) 2014-08-08 2017-07-24 Pharmacyclics Llc Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
EP3374361A1 (en) 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
WO2017151786A1 (en) 2016-03-01 2017-09-08 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
EP3756268A1 (de) 2018-02-23 2020-12-30 Industrieanlagen-Betriebsgesellschaft mbH Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
JP2023539729A (ja) * 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤の非晶質形態及びその製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119036A1 (en) * 2016-12-21 2018-06-28 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Also Published As

Publication number Publication date
EA202192320A1 (ru) 2021-11-16
JOP20210227A1 (ar) 2021-08-18
EP3927696A1 (en) 2021-12-29
JP2022523368A (ja) 2022-04-22
EP3927696B1 (en) 2023-10-18
PE20212067A1 (es) 2021-10-26
CN113474339A (zh) 2021-10-01
AU2020226723B2 (en) 2025-01-23
IL285675A (en) 2021-10-31
SG11202108909SA (en) 2021-09-29
TW202045495A (zh) 2020-12-16
CA3129623A1 (en) 2020-08-27
ES2966132T3 (es) 2024-04-18
AU2020226723A1 (en) 2021-08-19
US12269813B2 (en) 2025-04-08
UY38592A (es) 2020-08-31
BR112021016400A2 (pt) 2021-10-13
MA55019A (fr) 2021-12-29
EP3927696C0 (en) 2023-10-18
US20220127249A1 (en) 2022-04-28
KR20210131371A (ko) 2021-11-02
ECSP21067828A (es) 2021-11-18
MX2021010133A (es) 2021-09-23
PH12021552018A1 (en) 2022-09-19
WO2020169736A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
EP3927696B1 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
CN110305140B (zh) 二氢吡咯并嘧啶类选择性jak2抑制剂
CN101687855A (zh) 酞嗪酮衍生物及其作为治疗癌症的药物的用途
CN105793245B (zh) 药物化合物
JP7737991B2 (ja) Egfr阻害剤
JP2005526794A (ja) 薬剤
CN101759693B (zh) 苯骈异恶唑哌啶衍生物及在制备镇痛、镇静药物中的应用
WO2023078451A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN106687464B (zh) 大环rip2激酶抑制剂
US8436008B2 (en) Substituted heterocyclic compounds
CN120025312A (zh) 苯并氮杂卓衍生物
WO2014199933A1 (ja) 二環式含窒素芳香族ヘテロ環アミド化合物
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
JP7263473B2 (ja) Ttk阻害剤の固体形態
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN114585605A (zh) 药物化合物
US20230303542A1 (en) Solid forms of a parp14 inhibitor
HK40052643A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
EA045924B1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-(2-(трифторметил)пиридин-4-ил)-1h-пиразол-4-карбоксамида
WO2013107333A1 (zh) 哌嗪基嘧啶类衍生物及其制备方法和用途
WO2008033513A1 (en) ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS
CN117105872B (zh) 苯并二氮杂䓬类化合物及其制备方法与用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK40130821A (en) Formulations of an axl/mer inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052643

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant